Teva Launches Generic Version of Actonel

Published on: 

Teva announces the exclusive launch of its generic equivalent of Actonel in the US.


On June 1, 2015, Teva Pharmaceutical launched the generic version of Actavis’ Actonel (risedronate sodium) for the treatment and prevention of osteoporosis in post-menopausal women. The tablets, which come in 5, 30, and 35 mgs, were launched in the US with 180 days of market exclusivity, as Teva was the first to file for the generic version.


The drug helps to increase bone mass and reduce the risk of bone fractures, can help to treat and prevent osteoporosis in both men and women who are taking corticosteroids, and can help to treat Paget’s disease of the bone, according to a press release. The new generic marks the second osteoporosis treatment in Teva’s portfolio.

Source: Teva